Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe

Your AI-Trained Oncology Knowledge Connection!

scout
Advertisement

Anti-PD1, CTLA-4 Immunotherapy-Related Neurotoxicities ‘Not Uncommon’ in Patients With Melanoma

November 7, 2016
By Bryant Furlow
Article

Immune checkpoint inhibitor-related neurotoxicities are more frequent in clinical practice than clinical trials.

Immune checkpoint inhibitor-related neurotoxicities are more frequent in clinical practice than clinical trials-particularly among patients receiving ipilimumab (Yervoy) plus nivolumab (Opdivo) combination therapy (ipi+nivo), according to a retrospective single-institution cohort study reported online in the Annals of Oncology.

“Neurologic toxicity is not uncommon, and may be more frequent in patients treated with combination ipi+nivo,” reported coauthor James Larkin, MD, of the Royal Marsden Hospital in London, and colleagues.

“A prompt and considered approach is required to optimize outcomes in this group of patients,” they concluded. “There is a risk of neurological irAEs [immunotherapy-related adverse events] at any stage throughout the course of treatment with immune-checkpoint agents, however presentations within the first four months predominated in our cohort (8/10, 80%).”

Small numbers prevented “any definitive statements,” but findings from the review suggest the possibility that neurotoxicity might predict treatment response, the team noted.

Immune checkpoint blockade with anti-PD1 and anti-CTLA-4 antibodies has “greatly improved” survival among patients with advanced melanoma and previously published clinical trial data suggests a cumulative neurotoxicity incidence of less than 1% among patients with melanoma receiving ipilimumab, nivolumab, or pembrolizumab (Keytruda) monotherapy, the researchers reported.

But an emerging literature of case reports suggests that neurotoxicities might be more frequently associated with these immunotherapy agents than was initially believed, they noted.

The coauthors therefore reviewed medical records for 352 patients treated with immune checkpoint inhibitors between 2010 and 2015 at the Royal Marsden Hospital in London, including ipilimumab, nivolumab, or pembrolizumab monotherapy, or combination ipi+nivo therapy.

Among these patients, 2.8% overall experienced neurotoxicities of the central and peripheral nervous systems, ranging from grade 1 to grade 4 in severity. However, patients treated with combination ipilimumab plus nivolumab experienced a much higher neurological toxicities rate of 14%, the authors reported.

Examples of recorded neurotoxicities included peripheral neuropathy, phrenic neuropathy, bulbar palsy, sensory deficits such as the loss of fine touch sensations, pain, exertional dyspnea, inspiratory muscle weakness, and lumbosacral plexopathy.

“Our report presents several cases of neurological toxicity that do not neatly fit the characteristics of ‘typical’ neurological syndromes,” the researchers noted. “Both peripheral and central nervous systems may be affected and there does not appear to be a clear predominance of one over the other, although in our cohort the peripheral nervous system was more commonly impacts (70% versus 30% of cases).”

In some cases, neurotoxicity might have resulted from neuronal microvessel inflammation, and in some cases edema, they noted. The study team did not include dysgeusia (e.g., rancid or metallic taste sensations) as a reportable neurotoxicity in their records review.

Most immune checkpoint-related neurotoxicities “can be effectively reversed with corticosteroids,” the authors noted, although the cautioned that some patients did not respond to steroids. Among the five of these patients who were treated with corticosteroids, three responded well, the team noted. Six of the 10 patients with neurotoxicity had recovered fully at a median follow-up of 26.7 months.

 

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
A third of patients had a response [to lifileucel], and of the patients who have a response, half of them were alive at the 4-year follow-up.
We are seeing that, in those patients who have relapsed/refractory melanoma with survival measured as a few weeks and no effective treatments, about a third of these patients will have a response.
Related Content

Samples were analyzed using 40-GEP clinical testing standard operating procedures. The trial end points were LRFS and MFS.

DecisionDx-SCC Predicts Recurrence, Guides Imaging in Squamous Cell Carcinoma

Tim Cortese
September 10th 2025
Article

OncView™ Podcast: Immunotherapy Response Monitoring in Melanoma

OncView™ Podcast: Immunotherapy Response Monitoring in Melanoma

John M. Kirkwood, MD
September 10th 2025
Podcast

It was reported that though the treatment did not demonstrate statistical significance, it did yield a clinically meaningful improvement in PFS.

Novel Cancer Vaccine Combo Therapy Numerically Improves PFS in Melanoma

Tim Cortese
September 10th 2025
Article

On this episode of CancerNetwork’s podcast, Emily Smith, MD, discussed a patient case of basal cell carcinoma she and colleagues published in the journal ONCOLOGY.

Oncology Peer Review On-The-Go: Patient Case of Metastatic Basal Cell Carcinoma Arising From a Carcinosarcoma

Matthew Fowler;Emily Hoffman Smith, MD
September 10th 2025
Podcast

Innovative oncolytic virus therapies transform advanced melanoma treatment, enhance patient outcomes, and overcome resistance to traditional immunotherapies.

3 Things You Should Know About Managing Advanced Melanoma With Oncolytic Viral Immunotherapies

ONCOLOGY Staff
September 10th 2025
Article

Credit: Northwell Health

Singh to Advance Northwell’s Skin Cancer Program With Surgical Director Promotion

Ariana Pelosci
September 10th 2025
Article
Related Content

Samples were analyzed using 40-GEP clinical testing standard operating procedures. The trial end points were LRFS and MFS.

DecisionDx-SCC Predicts Recurrence, Guides Imaging in Squamous Cell Carcinoma

Tim Cortese
September 10th 2025
Article

OncView™ Podcast: Immunotherapy Response Monitoring in Melanoma

OncView™ Podcast: Immunotherapy Response Monitoring in Melanoma

John M. Kirkwood, MD
September 10th 2025
Podcast

It was reported that though the treatment did not demonstrate statistical significance, it did yield a clinically meaningful improvement in PFS.

Novel Cancer Vaccine Combo Therapy Numerically Improves PFS in Melanoma

Tim Cortese
September 10th 2025
Article

On this episode of CancerNetwork’s podcast, Emily Smith, MD, discussed a patient case of basal cell carcinoma she and colleagues published in the journal ONCOLOGY.

Oncology Peer Review On-The-Go: Patient Case of Metastatic Basal Cell Carcinoma Arising From a Carcinosarcoma

Matthew Fowler;Emily Hoffman Smith, MD
September 10th 2025
Podcast

Innovative oncolytic virus therapies transform advanced melanoma treatment, enhance patient outcomes, and overcome resistance to traditional immunotherapies.

3 Things You Should Know About Managing Advanced Melanoma With Oncolytic Viral Immunotherapies

ONCOLOGY Staff
September 10th 2025
Article

Credit: Northwell Health

Singh to Advance Northwell’s Skin Cancer Program With Surgical Director Promotion

Ariana Pelosci
September 10th 2025
Article
Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

259 Prospect Plains Rd, Bldg H,
Monroe, NJ 08831

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.